SecBot SecBot
6-K ·Filed Jul 9, 2026

AZN

ASTRAZENECA PLC
BEARISH
Impact 6/10
Horizonimmediate Processed4mo ago SEC0001654954-26-006554
Notable filing: 6-K
Actionable Insight ▼ Bearish

Expect a negative near-term reaction in AZN and partner Ionis (not directly named in filing) as the ATTR-CM program is now at risk. The monotherapy subgroup signal provides a potential path forward, but the lack of benefit on top of stabiliser is a significant headwind. Monitor the ESC Congress in August for further data and regulatory strategy updates.

DirectionBearish
Confidencehigh
Horizonimmediate

Drug in focus

AZN drug pipeline →

Wainua

▼ Bearish Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved (Dec 2023 in US; March 2025 in EU). ATTR-CM indication now likely delayed 3-5+ years if pursued at all.
Next catalyst
None dated

What to watchWainua's CARDIO-TTRansform Phase 3 failure in ATTR-CM (July 9, 2026) effectively closes off the much larger cardiomyopathy opportunity. Focus on the August 2026 ESC presentation for whether the monotherapy subgroup signal is strong enough to justify a second trial. For AZN, this is a manageable pipeline setback; IONS shareholders face a more meaningful valuation reset since ATTR-CM was a key growth driver for that stock.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$178.49
T+0 close · Jul 9, 2026 · via day close
Latest settled
−12.10%
T+60 · $156.90
Vs SPY
−13.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 9 $178.49entry
  2. T+1 · 4mo ago −3.85%α −4.29% · $171.61
  3. T+5 · 4mo ago −5.15%α −5.02% · $169.29
  4. T+20 · 3mo ago −9.81%α −12.05% · $160.99
  5. T+60 · 6w ago −12.10%α −13.73% · $156.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced that the CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary composite endpoint of CV mortality and recurrent CV events versus placebo. The drug was generally well tolerated, but adding it to standard of care including a majority on a stabiliser showed no statistically significant benefit. A prespecified monotherapy subgroup showed nominally significant fewer events, while no effect was seen in patients on stabiliser at baseline. The failure is a setback for AZN's pipeline in a large indication, but the stock impact may be moderated by the company's diversified portfolio and the monotherapy signal.

Key Facts

  • CARDIO-TTRansform Phase III trial did not meet the primary efficacy endpoint of composite CV mortality and recurrent CV events up to 140 weeks.
  • Trial enrolled 1,432 participants across 130 sites in 20 countries, randomised 1:1 to eplontersen 45 mg or placebo.
  • 57% of patients in each arm received a stabiliser at baseline; a further 24% in each arm initiated a stabiliser during the trial.
  • Prespecified monotherapy subgroup showed nominally significant fewer primary composite events; no treatment effect observed in patients on stabiliser at baseline.
  • Full data analysis will be shared at the European Society of Cardiology Congress in August 2026.

Financial Impact

The failure reduces the probability of approval for the ATTR-CM indication, which could have been a multibillion-dollar opportunity. No specific financial figures from the filing.

pipelinerevenuer&d

Risk Factors

  • Negative trial outcome could lead to write-down of asset value and reduced pipeline confidence.
  • Nominal significance in monotherapy subgroup may not be sufficient for regulatory approval without additional trials.
  • Competitors with approved stabilisers (tafamidis) maintain market dominance.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006554
Document: 0001654954-26-006554-index-headers.html0001654954-26-006554
Document: 0001654954-26-006554-index.html0001654954-26-006554
Document: 0001654954-26-006554.txt0001654954-26-006554

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Tue (16h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 9, 2026